Cleveland Clinic Cardiovascular Medicine Chair Steven Nissen, MD, has been to a lot of European Society of Cardiology (ESC) Congresses, but he says 2018’s meeting, which wrapped up in Munich at the end of August, really stands out. “This year featured an unusually large number of important late-breaking clinical trials, some of them breakthrough studies,” he says.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
In the video below, Dr. Nissen brings you up to speed in a few minutes on takeaways from several of those trials:
- The ATTR-ACT study of tafamidis for TTR cardiac amyloidosis
- The ARRIVE and ASCEND studies of aspirin for primary prevention of cardiovascular disease
- The AIMS study of potent angiotensin receptor blocker therapy to slow progression of Marfan syndrome
- The MITRA-FR investigation of MitraClip for severe secondary mitral regurgitation